Roche Scores Wins in AMD & COVID-19 in Big Week

Wet age-related macular degeneration is a leading cause of blindness in people over the age of 60. Genentech believes its investigational Port Delivery System with a ranibizumab (PDS) could be the first implant treatment for Wet AMD patients that provides continual drug delivery without the need for frequent injections.